

Rafael Duarte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10191823/publications.pdf>

Version: 2024-02-01

183
papers

15,851
citations

23544

58
h-index

18633

119
g-index

192
all docs

192
docs citations

192
times ranked

15392
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	1.3	12
2	Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: An age-matched cohorts study. <i>Clinical Infection in Practice</i> , 2022, 13, 100137.	0.2	5
3	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	2.5	8
4	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	1.0	4
5	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S�azary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1391-1401.	1.3	24
6	Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. <i>Trials</i> , 2021, 22, 70.	0.7	7
7	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664.	1.3	221
8	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	0.7	5
9	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2820-2825.	1.3	7
10	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
11	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	100
12	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
13	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
14	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 441-451.	1.3	22
15	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	1.3	196
16	Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document. <i>Bone Marrow Transplantation</i> , 2020, 55, 811-817.	1.3	6
17	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
18	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230

#	ARTICLE	IF	CITATIONS
19	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 133.	6.9	171
20	Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study. <i>Frontiers in Immunology</i> , 2020, 11, 1983.	2.2	0
21	Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo Osseo. <i>Nutrition</i> , 2020, 79-80, 110998.	1.1	4
22	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	1.3	163
23	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation â€” a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	1.7	5
24	Imaging in Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1770-1779.	2.0	26
25	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	1.3	147
26	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
27	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT â€” A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	2.2	10
28	Frequently asked questions regarding SARS-CoV-2 in cancer patientsâ€™ recommendations for clinicians caring for patients with malignant diseases. <i>Leukemia</i> , 2020, 34, 1487-1494.	3.3	50
29	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	2.2	3
30	How much has allogeneic stem cell transplantâ€™related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	2.5	89
31	Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1955-1962.	2.0	0
32	Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2019, 54, 142-145.	1.3	20
33	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019, 33, 508-517.	3.3	45
34	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. <i>EClinicalMedicine</i> , 2019, 15, 33-41.	3.2	8
35	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	2.2	140
36	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42

#	ARTICLE	IF	CITATIONS
37	Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1825-1831.	2.0	34
38	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	1.3	21
39	Fertility preservation from the point of view of hematopoietic cell transplant specialistsâ€™ a worldwide-web-based survey analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1747-1755.	1.3	5
40	Standards of CARE: what is considered â€œbest practiceâ€™ for the management of invasive fungal infections? A haematologistâ€™s and a mycologistâ€™s perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii3-ii8.	1.3	3
41	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
42	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	1.3	129
43	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
44	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	3.4	33
45	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope. <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	2.7	106
46	A paired trial comparing mononuclear cell collection in two machines for further inactivation through an inline or offline extracorporeal photopheresis procedure. <i>Transfusion</i> , 2019, 59, 340-346.	0.8	18
47	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1022-1028.	1.3	19
48	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	1.3	14
49	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	1.3	48
50	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
51	HSCT in Elderly Patients. , 2019, , 499-503.		3
52	ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 12-21.	1.3	91
53	Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 1030-1037.	1.3	31
54	Analysis of the Spanish CCR5-â††32 inventory of cord blood units: lower cell counts in homozygous donors. <i>Bone Marrow Transplantation</i> , 2018, 53, 741-748.	1.3	4

#	ARTICLE	IF	CITATIONS
55	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	1.3	19
56	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	1.3	75
57	Health-care professionals' perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 235-245.	1.3	13
58	Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. <i>Bone Marrow Transplantation</i> , 2018, 53, 417-421.	1.3	1
59	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	1.3	6
60	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	1.3	117
61	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	1.7	125
62	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
63	HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2018, 4, 54.	3.4	33
64	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2018, 156, 248-264.	2.0	14
65	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	1.3	186
66	Novel approaches to CMV after HCT: report from the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22-25 April 2017. <i>Future Science OA</i> , 2018, 4, FSO296.	0.9	1
67	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
68	The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. <i>Haematologica</i> , 2018, 103, 1698-1707.	1.7	24
69	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients" authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw580.	1.3	13
70	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2359-2367.	1.3	65
71	JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. <i>Bone Marrow Transplantation</i> , 2017, 52, 1367-1371.	1.3	61
72	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 1138-1143.	1.3	20

#	ARTICLE	IF	CITATIONS
73	Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. <i>Leukemia</i> , 2017, 31, 1752-1759.	3.3	23
74	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2017, 52, 811-817.	1.3	310
75	Mesenchymal stromal cells for steroid-refractory acute GvHD. <i>Bone Marrow Transplantation</i> , 2017, 52, 1577-1579.	1.3	14
76	Letemovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796
77	CAR-T cells: the narrow path between hope and bankruptcy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1588-1589.	1.3	24
78	Invasive fungal infections: managing the continuum of risk in HCT patients. <i>Future Microbiology</i> , 2017, 12, 843-846.	1.0	0
79	Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study. <i>Bone Marrow Transplantation</i> , 2017, 52, 326-329.	1.3	10
80	Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2017, 52, 191-196.	1.3	27
81	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182.	1.3	61
82	National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 717-725.	2.0	40
83	The EBMT“ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 357-362.	1.3	13
84	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	2.5	6
85	Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. <i>Croatian Medical Journal</i> , 2016, 57, 247-254.	0.2	11
86	Invasive fungal infections in <sc>AML</sc>/<sc>MDS</sc> patients treated with azacitidine: a risk worth considering antifungal prophylaxis?. <i>Mycoses</i> , 2016, 59, 516-519.	1.8	41
87	Development, preliminary usability and accuracy testing of the EBMT “eGVHD App”™ to support GvHD assessment according to NIH criteria”a proof of concept. <i>Bone Marrow Transplantation</i> , 2016, 51, 1062-1065.	1.3	18
88	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
89	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 906-912.	1.3	364
90	Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 2212-2220.	0.8	41

#	ARTICLE	IF	CITATIONS
91	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2386-2396.	1.3	226
92	The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). <i>Bone Marrow Transplantation</i> , 2016, 51, 1404-1407.	1.3	4
93	The current management landscape: aspergillosis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii23-ii29.	1.3	24
94	ECIL guidelines for treatment of <i>Pneumocystis jirovecii</i> pneumonia in non-HIV-infected haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2405-2413.	1.3	141
95	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	1.3	211
96	Gender and Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1145-1146.	2.0	11
97	Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually. <i>Bone Marrow Transplantation</i> , 2016, 51, 786-792.	1.3	338
98	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	13.9	436
99	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyético. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 584-588.	2.0	45
100	Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 718-726.	1.3	131
101	Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). <i>Transplant Infectious Disease</i> , 2015, 17, 221-233.	0.7	10
102	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. <i>Bone Marrow Transplantation</i> , 2015, 50, 1037-1056.	1.3	283
103	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. <i>Bone Marrow Transplantation</i> , 2015, 50, 476-482.	1.3	173
104	CCR5 $\Delta 32$ homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. <i>Lancet HIV</i> , 2015, 2, e236-e242.	2.1	52
105	Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. <i>Bone Marrow Transplantation</i> , 2015, 50, 34-39.	1.3	36
106	Reply to Lewis et al. <i>Clinical Infectious Diseases</i> , 2015, 60, 1285-1285.	2.9	2
107	Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT. <i>American Journal of Transplantation</i> , 2015, 15, 705-714.	2.6	15
108	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7

#	ARTICLE	IF	CITATIONS
109	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives” a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2015, 50, 781-789.	1.3	294
110	Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. Bone Marrow Transplantation, 2015, 50, 592-597.	1.3	11
111	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. American Journal of Clinical Pathology, 2015, 144, 484-492.	0.4	13
112	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplantation, 2015, 50, 1542-1550.	1.3	80
113	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2015, 56, 2812-2818.	0.6	5
114	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.	2.0	2,636
115	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia and Lymphoma, 2015, 56, 656-662.	0.6	32
116	Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. Bone Marrow Transplantation, 2015, 50, 274-281.	1.3	18
117	The lincRNA<i>HOTAIRM1</i>, located in the<i>HOXA</i> genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget, 2015, 6, 31613-31627.	0.8	78
118	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and SÅ©zary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. Journal of Clinical Oncology, 2014, 32, 3347-3348.	0.8	85
119	Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplantation, 2014, 49, 744-750.	1.3	145
120	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia, 2014, 28, 804-812.	3.3	59
121	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 389-396.	1.3	92
122	Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplantation, 2014, 49, 824-830.	1.3	87
123	Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia. Bone Marrow Transplantation, 2014, 49, 145-147.	1.3	5
124	Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica, 2014, 99, 1632-1637.	1.7	26
125	Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. Antimicrobial Agents and Chemotherapy, 2014, 58, 5758-5765.	1.4	99
126	Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT”NCI Chronic GVHD Task Force. Bone Marrow Transplantation, 2014, 49, 49-54.	1.3	42

#	ARTICLE	IF	CITATIONS
127	Prophylaxis and treatment of GVHD: EBMTâ€“ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014, 49, 168-173.	1.3	252
128	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	1.3	151
129	Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2015-2022.	2.0	42
130	Serum Galactomannan-Based Early Detection of Invasive Aspergillosis in Hematology Patients Receiving Effective Antimold Prophylaxis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1696-1702.	2.9	191
131	Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. <i>Haematologica</i> , 2014, 99, 603-604.	1.7	10
132	Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients. <i>Leukemia Research</i> , 2014, 38, 1199-1206.	0.4	9
133	Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. <i>Leukemia Research</i> , 2014, 38, 346-351.	0.4	4
134	Thawing of cryopreserved hematopoietic progenitor cells from apheresis with a new dryâ€“warming device. <i>Transfusion</i> , 2013, 53, 85-90.	0.8	12
135	Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. <i>Leukemia</i> , 2013, 27, 2157-2164.	3.3	60
136	Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. <i>European Journal of Haematology</i> , 2013, 91, 209-218.	1.1	41
137	Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Economics</i> , 2013, 16, 736-743.	1.0	4
138	Hematopoietic SCT in Europe: data and trends in 2011. <i>Bone Marrow Transplantation</i> , 2013, 48, 1161-1167.	1.3	110
139	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	0.6	246
140	European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. <i>Bone Marrow Transplantation</i> , 2012, 47, 1046-1050.	1.3	54
141	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194
142	Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. <i>Bone Marrow Transplantation</i> , 2012, 47, 1003-1005.	1.3	11
143	Reply to SB Mossad. <i>Bone Marrow Transplantation</i> , 2012, 47, 1380-1380.	1.3	0
144	Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 296-298.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Effect of Posaconazole on Cyclosporine Blood Levels and Dose Adjustment in Allogeneic Blood and Marrow Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6422-6424.	1.4	22
146	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 314-317.	2.0	42
147	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 788-793.	2.0	102
148	Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 318-323.	2.0	21
149	Clinical and microbiological epidemiology of <i>Streptococcus pneumoniae</i> bacteremia in cancer patients. <i>Journal of Infection</i> , 2012, 65, 521-527.	1.7	26
150	European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. <i>Transfusion</i> , 2012, 52, 2395-2400.	0.8	17
151	Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. <i>Leukemia Research</i> , 2012, 36, 990-997.	0.4	41
152	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
153	Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 657-663.	1.3	208
154	Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. <i>Current Medical Research and Opinion</i> , 2011, 27, 951-960.	0.9	30
155	Practical Aspects of Allogeneic Hematopoietic Cell Transplantation for Patients with Poor-Risk Chronic Lymphocytic Leukemia. <i>Scientific World Journal</i> , The, 2011, 11, 161-172.	0.8	2
156	The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. <i>Leukemia</i> , 2011, 25, 1-6.	3.3	68
157	Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. <i>Bone Marrow Transplantation</i> , 2011, 46, 52-58.	1.3	118
158	Effect of statins on outcomes in immunosuppressed patients with bloodstream infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 77-82.	1.3	9
159	Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2011, 35, e128-e130.	0.4	4
160	Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2011, 46, 733-739.	1.3	35
161	Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 4492-4499.	0.8	191
162	Bacteraemia due to extended-spectrum β -lactamase-producing <i>Escherichia coli</i> (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 333-341.	1.3	158

#	ARTICLE	IF	CITATIONS
163	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
164	Ameliorative potential of angiotensin1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2010, 32, 19.	0.8	28
165	P136 Allogeneic stem cell transplant in MDS: results of the Spanish registry. <i>Leukemia Research</i> , 2009, 33, S138-S139.	0.4	0
166	Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 41, 597-604.	1.3	109
167	Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome ⁺ positive leukemia. <i>Blood</i> , 2008, 112, 1005-1012.	0.6	366
168	Treatment of Anemia with Darbeoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study. <i>Blood</i> , 2008, 112, 3451-3451.	0.6	1
169	Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. <i>Bone Marrow Transplantation</i> , 2007, 40, 747-752.	1.3	15
170	Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2007, 40, 1007-1017.	1.3	17
171	Histopathology of graft versus host disease of the liver. <i>Histopathology</i> , 2007, 50, 727-738.	1.6	52
172	The Importance of Age, Fludarabine, and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 75-83.	2.0	36
173	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2006, 135, 201-209.	1.2	56
174	The effect of interleukin-7 on the alloreactivity of human T cells depends on the timing of its administration in relation to the allostimulus. <i>Bone Marrow Transplantation</i> , 2005, 35, 733-734.	1.3	1
175	Histologic Features of the Liver Biopsy Predict the Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 805-813.	2.0	37
176	Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2005, 106, 444-444.	0.6	6
177	Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. <i>Bone Marrow Transplantation</i> , 2004, 34, 815-817.	1.3	33
178	The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2257-2257.	0.6	0
179	Identification of non-na ⁺ ve CD4 ⁺ CD45RA ⁺ T cell subsets in adult allogeneic haematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2003, 32, 609-616.	1.3	14
180	The Synergy Between Stem Cell Factor (SCF) and Granulocyte Colony-stimulating Factor (G-CSF): Molecular Basis and Clinical Relevance. <i>Leukemia and Lymphoma</i> , 2002, 43, 1179-1187.	0.6	46

#	ARTICLE	IF	CITATIONS
181	Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. <i>Gene Therapy</i> , 2002, 9, 1359-1368.	2.3	52
182	SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. <i>Blood</i> , 2000, 96, 3422-3430.	0.6	51
183	Thyroid function and autoimmunity during treatment with G-CSF. <i>Clinical Endocrinology</i> , 1999, 51, 133-134.	1.2	11